AFLIBERCEPT
Information current as at: 1 June 2026
PBAC meeting date: July 2026
Submission Details
- Brand name:
-
- Eydenzelt®
- Form and strength:
-
- Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe
- Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL)
- Submission sponsor:
- CELLTRION HEALTHCARE AUSTRALIA PTY LTD
- Condition/indication:
(therapeutic use) -
- Branch retinal vein occlusion with macular oedema; Central retinal vein occlusion with macular oedema; Diabetic macular oedema; Subfoveal choroidal neovascularisation due to age-related macular degeneration
- Listing requested:
- To request listing of four new indications for the Eydenzelt brand of aflibercept that mirror the orginator brand's current listings. Eydenzelt was originally recommended for listing as a biosimilar brand of aflibercept at the November 2025 PBAC meeting for the subfoveal choroidal neovascularisation due to pathologic myopia indication.
- Funding program:
- PBS General Schedule
- Request authority level:
- Authority Required
- PBAC Submission type:
- New PBS listing (–)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - July 2026 PBAC meeting
-
Opportunity for consumer comment: - Open 25/03/2026 and close 20/05/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
1203
Page last updated
31 May 2026
v.9.19